Comparing SG&A Expenses: CRISPR Therapeutics AG vs Wave Life Sciences Ltd. Trends and Insights

Biotech SG&A Expenses: CRISPR vs. Wave Life Sciences

__timestampCRISPR Therapeutics AGWave Life Sciences Ltd.
Wednesday, January 1, 201451140002999000
Thursday, January 1, 20151340300010393000
Friday, January 1, 20163105600015994000
Sunday, January 1, 20173584500026975000
Monday, January 1, 20184829400039509000
Tuesday, January 1, 20196348800048869000
Wednesday, January 1, 20208820800042510000
Friday, January 1, 202110280200046105000
Saturday, January 1, 202210246400050513000
Sunday, January 1, 20237616200051292000
Monday, January 1, 202472977000
Loading chart...

In pursuit of knowledge

SG&A Expenses: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and Wave Life Sciences Ltd. from 2014 to 2023. Over this period, CRISPR Therapeutics AG's SG&A expenses surged by approximately 1,400%, peaking in 2021. In contrast, Wave Life Sciences Ltd. experienced a more modest increase of around 1,600%, with a steady rise each year.

Key Insights

  • CRISPR Therapeutics AG: The company saw its highest SG&A expenses in 2021, reflecting its aggressive expansion and investment in administrative capabilities.
  • Wave Life Sciences Ltd.: Despite a slower start, Wave Life Sciences Ltd. maintained a consistent upward trend, indicating a strategic focus on sustainable growth.

These trends highlight the differing strategies of these biotech leaders, offering valuable insights for investors and industry analysts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025